Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)

摘要

Background: Moderate to severe atopic dermatitis (AD) is associated with substantial patient burden despite current therapies.